In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Black Diamond Therapeutics Inc (NASDAQ: BDTX) was $3.73 for the day, up 0.27% from the previous closing price of $3.72. In other words, the price has increased by $0.27 from its previous closing price. On the day, 0.72 million shares were traded. BDTX stock price reached its highest trading level at $3.8 during the session, while it also had its lowest trading level at $3.615.
Ratios:
Our analysis of BDTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.73 and its Current Ratio is at 8.73. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Guggenheim on September 04, 2025, initiated with a Buy rating and assigned the stock a target price of $8.
On July 31, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $20.Raymond James initiated its Outperform rating on July 31, 2024, with a $20 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 19 ’25 when BIOTECH GROWTH N V sold 5,784,292 shares for $2.07 per share. The transaction valued at 11,997,749 led to the insider holds 2,733,547 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BDTX now has a Market Capitalization of 212368592 and an Enterprise Value of 90291592. As of this moment, Black’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.75. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.30. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.03 while its Price-to-Book (P/B) ratio in mrq is 1.60. Its current Enterprise Value per Revenue stands at 1.29 whereas that against EBITDA is 11.295.
Stock Price History:
The Beta on a monthly basis for BDTX is 3.13, which has changed by -0.0053333044 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, BDTX has reached a high of $4.14, while it has fallen to a 52-week low of $1.20. The 50-Day Moving Average of the stock is 25.22%, while the 200-Day Moving Average is calculated to be 59.56%.
Shares Statistics:
BDTX traded an average of 940.63K shares per day over the past three months and 1134370 shares per day over the past ten days. A total of 56.89M shares are outstanding, with a floating share count of 43.33M. Insiders hold about 23.89% of the company’s shares, while institutions hold 58.24% stake in the company. Shares short for BDTX as of 1757894400 were 7135726 with a Short Ratio of 7.59, compared to 1755216000 on 6898065. Therefore, it implies a Short% of Shares Outstanding of 7135726 and a Short% of Float of 18.0.
Earnings Estimates
A detailed examination of Black Diamond Therapeutics Inc (BDTX) is currently in progress, with 5.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.13 and low estimates of -$0.24.
Analysts are recommending an EPS of between $0.49 and $0.26 for the fiscal current year, implying an average EPS of $0.34. EPS for the following year is -$0.77, with 5.0 analysts recommending between -$0.49 and -$1.04.
